Arcturus Therapeutics Holdings raised to buy from neutral at Citigroup; price target raised to $20 from $8
ARCT•Citigroup raised its rating on Arcturus Therapeutics Holdings to buy from neutral and increased its price target to $20 from $8.
Related News
Comstock and Sierra Springs Opportunity Fund announce strategic engagement with Newmark for Nevada land-power-compute platform
LODE•
Miami International Holdings announces OCC clearing membership for its FCM
MIAX•
Merck says remigromig meets primary endpoint in pivotal BRUNELLO trial for diabetic macular edema
MRK•
Boxabl appoints Timothy Goldsmith, CPA, to board as audit committee chair
BXBL•
Clean Energy Fuels sells $30.7 million in federal tax credits from RNG portfolio
CLNE•